The positive interim data from the phase 2 clinical trial of CAN-2409 in non-metastatic prostate cancer is a significant development for Candel Therapeutics. This news directly impacts the company's stock as it reflects progress in their product pipeline, which is crucial for future revenue and growth prospects. Investors typically respond positively to such developments, leading to an increase in stock price in the short term.